BeOne Medicines AG (ONC)
NASDAQ: ONC · Real-Time Price · USD
316.54
-4.40 (-1.37%)
Oct 15, 2025, 2:02 PM EDT - Market open
BeOne Medicines AG Stock Forecast
Stock Price Forecast
The 10 analysts that cover BeOne Medicines AG stock have a consensus rating of "Strong Buy" and an average price target of $344.7, which forecasts a 8.90% increase in the stock price over the next year. The lowest target is $311 and the highest is $385.
Price Target: $344.7 (+8.90%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BeOne Medicines AG stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 5 | 7 | 7 | 7 | 8 | 8 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 9 | 9 | 9 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $345 → $385 | Buy | Maintains | $345 → $385 | +21.63% | Oct 8, 2025 |
| Barclays | Barclays | Buy Initiates $385 | Buy | Initiates | $385 | +21.63% | Sep 18, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $349 → $364 | Buy | Maintains | $349 → $364 | +15.00% | Aug 7, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $350 → $365 | Strong Buy | Maintains | $350 → $365 | +15.31% | Aug 7, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $321 → $345 | Buy | Maintains | $321 → $345 | +8.99% | Jul 17, 2025 |
Financial Forecast
Revenue This Year
37.38B
from 3.81B
Increased by 881.07%
Revenue Next Year
37.17B
from 37.38B
Decreased by -0.56%
EPS This Year
0.78
from -6.12
EPS Next Year
0.70
from 0.78
Decreased by -9.94%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 40.0B | 48.9B | |||
| Avg | 37.2B | 45.0B | |||
| Low | 35.1B | 41.4B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 949.0% | 31.6% | |||
| Avg | 875.6% | 21.0% | |||
| Low | 822.3% | 11.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.56 | 3.94 | |||
| Avg | 0.70 | 2.68 | |||
| Low | 0.21 | 1.50 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 459.7% | |||
| Avg | - | 281.5% | |||
| Low | - | 113.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.